ArticleMikrochimica acta2025
Bientropy-powered catalysis crosslinked ultrasensitive nanobiosensor for precise NIR light-regulated imaging of tumor biomarkers.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Owing to the protease-free and hairpin DNA primers-free design of entropy-powered catalysis (EPC), nanobiosensors constructed from this amplification protocol show promising potential for detecting tumor biomarkers in live biosystems. Nevertheless, EPC's single-round signal enhancement and perpetual activation during bio-delivery severally restrict its sensitivity and precision in responding to low-concentration analytes. To overcome these restrictions, this study first links together fuel strands produced by two separate EPC modules, thus establishing an ultrasensitive nanobiosensor that implements an exceptional crosslinked bientropy-powered catalysis with more powerful two-round amplification capacity. Following that, one DNA segment is embedded with a photocleavable bond to block the analyte's recognition site, whereby a near-infrared light (NIR)-regulated strategy facilitated by upconversion luminescence is utilized to precisely activate the biosensing operation. Our conceptual proof is validated by determining microRNA-21, a low-abundance biomarker inclined to be overexpressed in various malignant tumors. In addition to ultra-high sensitivity (with a remarkably low limit of detection of 32.44 fM) and satisfactory specificity (discriminating even single-nucleotide mutations) in buffered environments, this bientropy-powered catalysis crosslinked nanobiosensor enables reliable imaging assays in both live cells and animals, offering a potent toolbox for cancer diagnostics.
Indexed as
Identifiers
41003734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.